Protalix End Period Cash Flow from 2010 to 2024

PLX Stock  USD 1.19  0.02  1.65%   
Protalix Biotherapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, Protalix Biotherapeutics End Period Cash Flow regression line of annual values had r-squared of  0.08 and arithmetic mean of  39,809,150. View All Fundamentals
 
End Period Cash Flow  
First Reported
1996-09-30
Previous Quarter
20.4 M
Current Value
23.6 M
Quarterly Volatility
24.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix main balance sheet or income statement drivers, such as Interest Expense of 2.8 M, Other Operating Expenses of 31.5 M or Operating Income of 11 M, as well as many exotic indicators such as Price To Sales Ratio of 1.74, Dividend Yield of 0.0 or PTB Ratio of 3.4. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
  
This module can also supplement Protalix Biotherapeutics' financial leverage analysis and stock options assessment as well as various Protalix Biotherapeutics Technical models . Check out the analysis of Protalix Biotherapeutics Correlation against competitors.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Latest Protalix Biotherapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Protalix Biotherapeutics over the last few years. It is Protalix Biotherapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Pretty Stable
   End Period Cash Flow   
       Timeline  

Protalix End Period Cash Flow Regression Statistics

Arithmetic Mean39,809,150
Geometric Mean28,787,041
Coefficient Of Variation60.21
Mean Deviation19,355,080
Median37,808,000
Standard Deviation23,970,758
Sample Variance574.6T
Range85.6M
R-Value(0.28)
Mean Square Error570.4T
R-Squared0.08
Significance0.31
Slope(1,498,749)
Total Sum of Squares8044.4T

Protalix End Period Cash Flow History

202431.8 M
202323.6 M
202217.1 M
202139 M
202018.3 M
201917.8 M
201837.8 M

About Protalix Biotherapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Protalix Biotherapeutics income statement, its balance sheet, and the statement of cash flows. Protalix Biotherapeutics investors use historical funamental indicators, such as Protalix Biotherapeutics's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Protalix Biotherapeutics investors may use each financial statement separately, they are all related. The changes in Protalix Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Protalix Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Protalix Biotherapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow23.6 M31.8 M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Protalix Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protalix Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protalix Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protalix Biotherapeutics Stock:
Check out the analysis of Protalix Biotherapeutics Correlation against competitors.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Protalix Stock analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.39)
Earnings Share
0.09
Revenue Per Share
0.97
Quarterly Revenue Growth
0.217
Return On Assets
0.0933
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.